Biodel's insulin comes through in Phase II

Connecticut biotech Biodel ($BIOD) is touting mid-stage results for its long-acting insulin, as the in-development BIOD-531 better controlled glucose than two Eli Lilly ($LLY) therapies. In a study on Type 2 diabetics with moderate insulin resistance, Biodel's drug beat out Lilly's Humalog and Humulin in controlling blood sugar after two meals, the company said. Biodel said it's now working with the FDA to design a late-stage program and move BIOD-531 both for insulin-resistant patients and broader populations. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.